These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 16835191

  • 1. The rise and fall of Natrecor for congestive heart failure: implications for drug policy.
    Kesselheim AS, Fischer MA, Avorn J.
    Health Aff (Millwood); 2006; 25(4):1095-102. PubMed ID: 16835191
    [Abstract] [Full Text] [Related]

  • 2. Nesiritide--not verified.
    Sackner-Bernstein J, Aaronson KD.
    N Engl J Med; 2005 Oct 06; 353(14):1525-7; author reply 1525-7. PubMed ID: 16207860
    [No Abstract] [Full Text] [Related]

  • 3. Nesiritide - not verified.
    Topol EJ.
    N Engl J Med; 2005 Jul 14; 353(2):113-6. PubMed ID: 16014879
    [No Abstract] [Full Text] [Related]

  • 4. Nesiritide: the wrong controversy.
    Somberg JC.
    Am J Ther; 2005 Jul 14; 12(5):377-8. PubMed ID: 16148421
    [No Abstract] [Full Text] [Related]

  • 5. [Nesiritide in heart failure: commercial success or therapeutic advance?].
    Stampfli T, Perrier A.
    Rev Med Suisse; 2006 Jan 25; 2(50):295-8. PubMed ID: 16503047
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The lost decade of nesiritide.
    Topol EJ.
    N Engl J Med; 2011 Jul 07; 365(1):81-2. PubMed ID: 21732841
    [No Abstract] [Full Text] [Related]

  • 8. Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment.
    Munger MA, Ng TM, Van Tassell BW.
    Pharmacotherapy; 2007 May 07; 27(5):619-25. PubMed ID: 17461695
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide.
    Noviasky JA.
    Pharmacotherapy; 2007 May 07; 27(5):626-32. PubMed ID: 17461696
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL.
    J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM, Studdert DM, Brennan TA.
    N Engl J Med; 2009 Apr 09; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Nesiritide: harmful or harmless?
    Dorsch MP, Rodgers JE.
    Pharmacotherapy; 2006 Oct 09; 26(10):1465-78. PubMed ID: 16999657
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V, Baylor NW.
    Pediatrics; 2011 May 09; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [Abstract] [Full Text] [Related]

  • 20. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003.
    Cowden AL, Katz KA.
    Br J Dermatol; 2006 May 09; 154(5):950-8. PubMed ID: 16634900
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.